What one share of Coherus Oncology holds
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.
Coherus Oncology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.39 |
|---|---|
| Profit | −$1.00 |
| Cash and investments | $0.68 |
| Book value | $0.39 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | — | −$15.85 | $0.86 | −$9.62 | — | — |
| 2013 | — | −$16.10 | $0.11 | $4.52 | — | −$20.07 |
| 2014 | — | −$10.64 | $0.35 | −$3.27 | — | — |
| 2015 | — | −$6.01 | $0.17 | −$3.08 | — | −$0.16 |
| 2016 | — | −$3.04 | $0.16 | −$6.18 | — | $0.45 |
| 2017 | — | −$4.48 | $0.09 | −$3.86 | — | $0.51 |
| 2018 | — | −$3.22 | $0.01 | −$2.46 | — | −$0.56 |
| 2019 | $4.87 | $1.23 | $0.02 | $0.36 | — | $1.50 |
| 2020 | $5.70 | $1.58 | $0.09 | $1.76 | — | $3.87 |
| 2021 | $4.33 | −$3.81 | $0.02 | −$0.51 | — | $1.27 |
| 2022 | $2.72 | −$3.76 | $0.03 | −$3.13 | — | −$1.74 |
| 2023 | $2.73 | −$2.53 | $0.00 | −$1.86 | — | −$1.72 |
| 2024 | $0.23 | $0.25 | — | — | — | −$1.14 |
| 2025 | $0.36 | $1.43 | — | — | — | $0.50 |
Common questions about Coherus Oncology
How much does one share of Coherus Oncology earn?
Over the last 12 months, Coherus Oncology lost $1.00 for each share on $0.39 of sales.
Does Coherus Oncology pay a dividend?
Coherus Oncology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Coherus Oncology’s book value per share?
Coherus Oncology’s book value is $0.39 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Coherus Oncology have?
Each share of Coherus Oncology has $0.68 of cash and investments, as of June 30, 2026.
Has Coherus Oncology bought back shares?
Coherus Oncology’s share count rose about 5525% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.